Chambers JD - Search Results

1

Are Drug Novelty Characteristics Associated With Greater Health Benefits?

Levine AA, Enright DE, Clifford KA, Kowal S, Chambers JD. Levine AA, et al. Among authors: chambers jd. Appl Health Econ Health Policy. 2024 Nov;22(6):827-832. doi: 10.1007/s40258-024-00910-3. Epub 2024 Sep 3. Appl Health Econ Health Policy. 2024. PMID: 39225746

2

Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval.

Chambers JD, Thorat T, Wilkinson CL, Salem M, Subedi P, Kamal-Bahl SJ, Neumann PJ. Chambers JD, et al. Appl Health Econ Health Policy. 2017 Apr;15(2):227-235. doi: 10.1007/s40258-016-0291-9. Appl Health Econ Health Policy. 2017. PMID: 27832480

3

What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?

Panzer AD, Margaretos NM, Lai RC, Enright DE, Chambers JD. Panzer AD, et al. Among authors: chambers jd. Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1307-1311. doi: 10.1002/pds.4992. Epub 2020 Mar 25. Pharmacoepidemiol Drug Saf. 2020. PMID: 32212282

4

Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?

Chambers JD, Margaretos NM, Enright DE, Wang R, Ye X. Chambers JD, et al. Pharmacoeconomics. 2022 Feb;40(2):225-232. doi: 10.1007/s40273-021-01096-5. Epub 2021 Oct 26. Pharmacoeconomics. 2022. PMID: 34697718

5

Are Medical Devices Cost-Effective?

Chambers JD, Silver MC, Berklein FC, Cohen JT, Neumann PJ. Chambers JD, et al. Appl Health Econ Health Policy. 2022 Mar;20(2):235-241. doi: 10.1007/s40258-021-00698-6. Epub 2021 Nov 25. Appl Health Econ Health Policy. 2022. PMID: 34820784

6

Characterizing health plan evidence review practices.

Panzer AD, Enright DE, Graff J, Chambers JD. Panzer AD, et al. Among authors: chambers jd. J Manag Care Spec Pharm. 2022 Sep;28(9):1053-1058. doi: 10.18553/jmcp.2022.28.9.1053. J Manag Care Spec Pharm. 2022. PMID: 36001106 Free PMC article.

7

Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.

Chambers JD, Enright DE, Panzer AD, Cohen JT, Ollendorf DA, Neumann PJ. Chambers JD, et al. J Manag Care Spec Pharm. 2023 Mar;29(3):257-264. doi: 10.18553/jmcp.2023.29.3.257. J Manag Care Spec Pharm. 2023. PMID: 36840954 Free PMC article.

8

Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease.

Lin PJ, Levine A, Rucker J, Chambers JD. Lin PJ, et al. Among authors: chambers jd. Alzheimers Dement. 2023 Aug;19(8):3654-3669. doi: 10.1002/alz.12965. Epub 2023 Feb 28. Alzheimers Dement. 2023. PMID: 36852834

9

Specialty drug coverage varies between health plans' medical and pharmacy benefit policies.

Levine AA, Panzer AD, Kauf TL, O'Sullivan AK, Strand L, Chambers JD. Levine AA, et al. Among authors: chambers jd. J Manag Care Spec Pharm. 2023 Jun;29(6):607-613. doi: 10.18553/jmcp.2023.29.6.607. J Manag Care Spec Pharm. 2023. PMID: 37276044 Free PMC article.

10

Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act.

Chambers JD, Clifford KA, Enright DE, Neumann PJ. Chambers JD, et al. JAMA Netw Open. 2023 Aug 1;6(8):e2329006. doi: 10.1001/jamanetworkopen.2023.29006. JAMA Netw Open. 2023. PMID: 37581890 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

122 results

Search Page

Filters